Get the Stockscreener App
182.64
22.75%
33.85
Axsome Therapeutics Inc stock is traded at $182.64, with a volume of 3.04M.
It is up +22.75% in the last 24 hours and up +20.55% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$148.79
Open:
$158.49
24h Volume:
3.04M
Relative Volume:
5.63
Market Cap:
$9.21B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-27.97
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+18.88%
1M Performance:
+20.55%
6M Performance:
+74.96%
1Y Performance:
+115.86%
1-Day Range:
$158.49
$184.40
1-Week Range:
$148.13
$184.40
52-Week Range:
$79.19
$184.40
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
182.64 | 7.50B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing - ts2.tech
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review - ts2.tech
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 - The Globe and Mail
Axsome Therapeutics Stock Skyrockets: What’s Next? - StocksToTrade
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation - ts2.tech
Key Takeaways - StocksToTrade
Axsome’s Surprising Surge: What’s Next ? - timothysykes.com
From Haiti to Wall Street to Big Pharma: Herriot Tabuteau is on a $6B mission to heal the brain - AOL.com
Axsome Therapeutics price target raised to $217 from $202 at Mizuho - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com Nigeria
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing - ts2.tech
Axsome Therapeutics says AXS-12 NDA submission on track for January - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock - Investing.com
Axsome Therapeutics Stock Surge Analysis - timothysykes.com
Axsome Therapeutics: Late-Stage CNS Pipeline and Regulatory Tailwinds Support Buy Rating - TipRanks
Mizuho raises Axsome Therapeutics stock price target on regulatory progress - Investing.com
Axsome stock jumps on FDA priority review for Alzheimer’s agitation drug - Investing.com
Mizuho raises Axsome Therapeutics stock price target on regulatory progress By Investing.com - Investing.com UK
Pharmaceutical Stocks To Follow NowDecember 31st - MarketBeat
Mizuho Lifts Price Target on Axsome Therapeutics to $217 From $202, Keeps Outperform Rating - marketscreener.com
Oppenheimer raises Axsome Therapeutics stock price target to $220 on FDA news - Investing.com
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating - 富途牛牛
Axsome Therapeutics announces FDA acceptance, priority review of AXS-05 sNDA - TipRanks
Morgan Stanley reiterates Overweight rating on Axsome stock with $196 target - Investing.com
Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation Drug - Investor's Business Daily
Axsome’s Auvelity for Alzheimer’s agitation gets priority review - BioWorld MedTech
Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy - Stocktwits
Axsome Therapeutics Poised for Growth as AXS-05 Nears FDA Approval - timothysykes.com
Pharma Stock Soars to Record Highs on FDA Buzz - Schaeffer's Investment Research
Axsome nabs speedy review of Alzheimer's agitation drug hopeful - FirstWord Pharma
Why Is Axsome Therapeutics Stock Soaring Wednesday?Axsome Therapeutics (NASDAQ:AXSM) - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday - Benzinga
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - Seeking Alpha
Axsome Therapeutics stock hits all-time high at 160.6 USD By Investing.com - Investing.com Nigeria
Axsome Therapeutics stock hits all-time high at 160.6 USD - Investing.com
Axsome Therapeutics shares gain 8.3% after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
Axsome Therapeutics stock holds Buy rating at Truist on AXS-05 sNDA acceptance - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Has Debt But No Earnings; Should You Worry? - 富途牛牛
Axsome stock gets Buy rating from TD Cowen on FDA priority review - Investing.com
Needham & Company LLC Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome stock surges after FDA grants priority review for Alzheimer’s drug - Investing.com
Why Axsome Therapeutics Shares Are Slipping Now - TipRanks
Axsome Therapeutics Says US FDA Accepts New-Drug Application Filing for Alzheimer's Disease Agitation Drug - marketscreener.com
Axsome Therapeutics to File AXS-12 New Drug Application in Narcolepsy After FDA Feedback - marketscreener.com
Axsome Advances AXS-12 Toward NDA Filing for Narcolepsy - TipRanks
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease agitation - Seeking Alpha
Axsome Therapeutics shares gain 1.4% premarket after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation - The Manila Times
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission - The Manila Times
FDA Accepts Axsome's SNDA For AXS-05 In Alzheimer's Agitation With Priority Review - Nasdaq
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 02 '25 |
Option Exercise |
8.02 |
49,252 |
395,001 |
56,481 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 03 '25 |
Option Exercise |
8.02 |
20,163 |
161,707 |
27,392 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 04 '25 |
Option Exercise |
8.02 |
10,558 |
84,675 |
17,787 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 02 '25 |
Sale |
144.59 |
49,252 |
7,121,347 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 03 '25 |
Sale |
146.94 |
20,163 |
2,962,751 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 04 '25 |
Sale |
148.18 |
10,558 |
1,564,484 |
7,229 |
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):